Compare Nokia Corp (NOK) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Natera Inc. Common Stock — how do they compare? Nokia Corp trades at $9.36 (market cap $54.54B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Nokia Corp and Natera Inc. Common Stock are close in size by market cap, and Nokia Corp pays a 1.66% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 65 Days and Natera Inc. Common Stock for 0 Days on average.
| NOK | NTRA | |
|---|---|---|
Market Cap | $54.54B | $57.03B |
Volume | 76,721,489 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $16.83 | $425.64 |
52-Week Low | $5.55 | $179.42 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $52.57B | $56.18B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.86, down 0.4% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships in AI, satellite communications, and network automation, including an expanded collaboration with Microsoft announced on September 17, 2026.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (59.6%) and a consensus price target of $17.50, implying significant upside. Key opportunities include growth in AI and cloud infrastructure demand, while risks involve competitive pressures and inconsistent earnings performance. Cash flow volatility remains a concern, with net cash flow negative in 2025 and 2026.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
